Aside from these normal conditions, PODXL has been found to be upregulated in various malignancies, and its strong expression, particularly in the cell membrane, associates with a more aggressive tumor phenotype and a poor prognosis in periampullary10, breast11, colorectal12–15 ovarian16, and bladder cancers17, as well as in glioblastoma18. Here, PODXL is linked to neoplasm.